Viveo Valuation Multiples

Viveo is valued at $64M as of October 2026, a 0.3x revenue multiple. In the last 12 months, Viveo revenue was $2.3B and Viveo EBITDA was $153M.

See full Viveo profile

Viveo Overview

About Viveo

Viveo is a Brazilian healthcare group based in Ribeirao Preto, in the state of Sao Paulo, that distributes and manufactures medical products and medicines. It was founded in 1996 by Carlos Mafra as a hospital supplies distributor and was long known as Mafra Hospitalar. DNA Capital, an investment firm linked to the Bueno family, entered the business in 2016 and later took control through its funds. The group grew by acquisition, buying the vaccine distributor Tecnocold in 2017, the consumer and hospital products maker Cremer in 2018 and more than twenty other companies in distribution, laboratory supplies, sterile solutions and patient support. It listed on the Sao Paulo stock exchange in August 2021 under the ticker VVEO3 in an offering of R$1.9 billion. After an aggressive acquisition cycle it began selling assets in 2025 to reduce debt. It reported net revenue of R$2.9 billion in the second quarter of 2026.


Founded

1996

HQ

Brazil

Employees

N/A

Financials (LTM)

Revenue: $2.3B
EBITDA: $153M

EV

$732M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Viveo Financials

Viveo reported last 12-month revenue of $2.3B and EBITDA of $153M.

In the same LTM period, Viveo generated $458M in gross profit, $153M in EBITDA, and had net loss of ($8M).

Revenue (LTM)


Viveo P&L

In the most recent fiscal year, Viveo reported revenue of $2.3B and EBITDA of $189M.

Viveo is profitable as of last fiscal year, with gross margin of 14%, EBITDA margin of 8%, and net margin of 0%.

See analyst estimates for Viveo
LTMLast FY202320242025202620272028
Revenue$2.3B$2.3B$2.2B$2.3B$2.3B
Gross Profit$458M$331M$340M$256M$331M
Gross Margin20%14%16%11%14%
EBITDA$153M$189M$176M($157M)$189M
EBITDA Margin7%8%8%(7%)8%
EBIT Margin4%5%6%(5%)5%
Net Profit($8M)$4M$71M($277M)$4M
Net Margin(0%)0%3%(12%)0%
Net Debt-$588M---

Financial data powered by Morningstar, Inc.

Viveo Stock Performance

Viveo has current market cap of $64M, and enterprise value of $732M.

Market Cap Evolution


Viveo's stock price is $0.20.

Viveo share price increased by 33.3% in the last 30 days, and decreased by 24.5% in the last year.

Viveo has an EPS (earnings per share) of $0.01.

See more trading valuation data for Viveo
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$732M$64M-0.5%33.3%47.1%-24.5%$0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Viveo Valuation Multiples

Viveo trades at 0.3x EV/Revenue multiple, and 4.8x EV/EBITDA.

See NTM and 2027E valuation multiples for Viveo

EV / Revenue (LTM)


Viveo Financial Valuation Multiples

As of October 21, 2026, Viveo has market cap of $64M and EV of $732M.

Viveo has a P/E ratio of (8.0x).

LTMLast FY202320242025202620272028
EV/Revenue0.3x0.3x0.3x0.3x0.3x
EV/EBITDA4.8x3.9x4.2x(4.7x)3.9x
EV/EBIT7.7x6.7x5.9x(6.2x)6.7x
EV/Gross Profit1.6x2.2x2.2x2.9x2.2x
P/E(8.0x)17.7x0.9x(0.2x)17.7x
EV/FCF24.1x29.5x(3.1x)(24.7x)29.5x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Viveo Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Viveo Margins & Growth Rates

Viveo grew revenue by 3% but EBITDA decreased by 19% in the last fiscal year.

In the most recent fiscal year, Viveo reported gross margin of 14%, EBITDA margin of 8%, and net margin of 0%.

See estimated margins and future growth rates for Viveo

Viveo Margins

Last FY202420252026202720282029
Gross Margin14%11%14%-
EBITDA Margin8%(7%)8%6%
EBIT Margin5%(5%)5%4%
Net Margin0%(12%)0%(0%)
FCF Margin1%(1%)1%-

Viveo Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth3%5%1%3%
Gross Profit Growth-(25%)29%-
EBITDA Growth(19%)(190%)(220%)(19%)
EBIT Growth(13%)(196%)(193%)(13%)
Net Profit Growth(340%)(493%)(101%)(340%)
FCF Growth-(87%)(184%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

Viveo Operational KPIs

Viveo's Rule of 40 is 10% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Viveo's Rule of X is 15% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Viveo
LTMLast FY202320242025202620272028
Rule of 4012%10%---
Bessemer Rule of X20%15%---
S&M Expenses to Revenue-3%3%4%3%
G&A Expenses to Revenue-8%8%9%8%
Opex to Revenue-10%10%16%10%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Viveo Competitors

Viveo competitors include Microbot Medical, Gallmetzer Healthcare, AXIL Brands, Meditera, Navamedic, Kewaunee Scientific, Rockwell Medical, Nortech Systems, TempraMed Technologies and Laxmi Dental.

Most Viveo public comparables operate across Medical Supplies.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Microbot Medical-($14M)----
Gallmetzer Healthcare$66M$1M1.1x-70.9x-
AXIL Brands$31M$3M1.0x0.9x9.5x-
Meditera$58M$3M0.5x-10.2x-
Navamedic$60M$3M0.8x0.8x15.0x8.1x
Kewaunee Scientific$282M$24M0.4x-5.0x-
Rockwell Medical$69M($2M)0.3x0.3x(8.3x)20.6x
Nortech Systems$118M$2M0.4x-20.1x-

This data is available for Pro users. Sign up to see all Viveo competitors and their valuation data.

Start Free Trial

Viveo VC Funding History

Before going public, Viveo raised funding across 1 round.


Viveo Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Dec-15Undisclosed stageDNA Capital--Cromossomo Participações IV agreed an initial investment in CM Hospitalar, the medical products distributor subsequently branded Viveo. The investment agreement was signed on 31 December 2015 and took effect on 1 March 2016, with Cromossomo Participações IV identified as the investment vehicle. The resulting initial interest was reported as 37% of the business. The purchase price was not established from the reviewed disclosures. Founded in 1996 by Carlos Alberto Mafra, the company distributed hospital medicines and consumables. DNA supported a strategy of expanding into an integrated supplier serving hospitals, clinics and laboratories, subsequently using acquisitions to enter vaccines, manufacturing and additional distribution channels. The later 2020 control investment is recorded separately.

Acquisitions by Viveo

Viveo has acquired 28 companies to date.

Last acquisition by Viveo was on June 5th 2023. Viveo acquired Neve for $14M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Viveo

Neve
Far-me
Nutrifica
Pro Infusion
Description
Neve is a Brazilian manufacturer of hospital products based in Braganca Paulista in the interior of the state of Sao Paulo. It was founded in 1986 and makes products in four lines: surgical, orthopedic, gowning and protection. Its products are made at a plant in Braganca Paulista and it employs about 400 people. It supplies more than 1,500 hospitals across Brazil. Viveo estimated its annual net revenue at R$95 million with EBITDA of R$11 million before synergies. The business was bought by Viveo in 2023 through its subsidiary Cremer and adds to the group's manufacturing and sale of medical products for hospitals and clinics. The company sells to hospitals and clinics directly and operates as a private limited company.
Far-me is a Brazilian pharmacy chain specializing in personalized medication dispensing for polypharmacy patients. It sorts prescriptions into daily, time-stamped sachets delivered monthly to homes across São Paulo and other regions. The service uses automated blister packaging to reduce errors and improve adherence for chronic conditions. Far-me partners with over 500 pharmacies and operates production facilities in São Paulo state. Launched in 2019, it serves thousands of patients with pharmacist consultations and app-based refill management.
Nutrifica operates in Brazil with a business focused on compounding and sale of enteral and parenteral nutrition formulas. Its products or services form part of the healthcare supply chain served by Viveo and its subsidiaries.
Pro Infusion operates in Brazil with a business focused on sterile pharmaceutical compounding for cancer therapies and parenteral nutrition. Its products or services form part of the healthcare supply chain served by Viveo and its subsidiaries.
HQ CountryBrazilBrazilBrazilBrazil
HQ City
Braganca Paulista
Belo Horizonte
Brasília
São Paulo
Deal Date5 Jun 20233 Feb 202322 Aug 202211 May 2022
Valuation$14M$4Mundisclosed$54M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Viveo acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Viveo

Viveo has invested in 2 companies to date.

Latest investment by Viveo was on September 5th 2022. Viveo invested in X Farmácia in their $3M Seed round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Viveo

X Farmácia
Far-me
Description
X Farmácia is a Brazil-based e-commerce pharmacy offering prescription and OTC medications with free shipping on orders over R$99.99 and deliveries within two hours in major cities like São Paulo and Rio de Janeiro. Competing with chains through lower prices, it provides a user-friendly app for browsing generics, beauty products, and health supplements with real-time stock and pharmacist chat support.
Far-me is a Brazilian pharmacy chain specializing in personalized medication dispensing for polypharmacy patients. It sorts prescriptions into daily, time-stamped sachets delivered monthly to homes across São Paulo and other regions. The service uses automated blister packaging to reduce errors and improve adherence for chronic conditions. Far-me partners with over 500 pharmacies and operates production facilities in São Paulo state. Launched in 2019, it serves thousands of patients with pharmacist consultations and app-based refill management.
HQ CountryBrazilBrazil
HQ City
São Paulo
Belo Horizonte
Deal Date5 Sep 20226 Oct 2020
RoundSeedSeries A
Raised$3Mundisclosed
InvestorsViveoViveo
Valuationundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Viveo investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Viveo

When was Viveo founded?Viveo was founded in 1996.
Where is Viveo headquartered?Viveo is headquartered in Brazil.
Is Viveo publicly listed?Yes, Viveo is a public company listed on B3.
What is the stock symbol of Viveo?Viveo trades under VVEO3 ticker.
When did Viveo go public?Viveo went public in 2021.
Who are competitors of Viveo?Viveo main competitors include Microbot Medical, Gallmetzer Healthcare, AXIL Brands, Meditera, Navamedic, Kewaunee Scientific, Rockwell Medical, Nortech Systems, TempraMed Technologies, Laxmi Dental.
What is the current market cap of Viveo?Viveo's current market cap is $64M.
What is the current revenue of Viveo?Viveo's last 12 months revenue is $2.3B.
What is the current revenue growth of Viveo?Viveo revenue growth (NTM/LTM) is 5%.
What is the current EV/Revenue multiple of Viveo?Current revenue multiple of Viveo is 0.3x.
What is the current EBITDA of Viveo?Viveo's last 12 months EBITDA is $153M.
What is Viveo's EBITDA margin?Viveo's last 12 months EBITDA margin is 7%.
What is the current EV/EBITDA multiple of Viveo?Current EBITDA multiple of Viveo is 4.8x.
What is the current FCF of Viveo?Viveo's last 12 months FCF is $30M.
What is Viveo's FCF margin?Viveo's last 12 months FCF margin is 1%.
What is the current EV/FCF multiple of Viveo?Current FCF multiple of Viveo is 24.1x.
How many companies Viveo has acquired to date?As of October 2026, Viveo has acquired 28 companies.
What was the largest acquisition by Viveo?$83M acquisition of Expressa Distribuidora de Medicamentos on 27th December 2019 was the largest M&A Viveo has done to date.
In how many companies Viveo has invested to date?As of October 2026, Viveo has invested in 2 companies.
What was the last Viveo investment?On 5th September 2022 Viveo invested in X Farmácia, participating in a $3M Seed round.

See public comps similar to Viveo

Lists including Viveo

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial